The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech

The article highlights three defensive dividend names with attractive yields: AbbVie at 3.2%, Procter & Gamble at 3.0%, and Enterprise Products Partners at 5.5%. It argues each has strong long-term cash generation and income durability, with Enterprise covering distributions 1.7x by distributable cash flow and AbbVie supported by newer immunology drugs Skyrizi and Rinvoq. The piece is broadly positive on dividend stocks as a rotation away from tech, but it is primarily opinion/stock-picking commentary rather than new market-moving information.

Analysis

This is less a bullish call on three names than a signal that the market is quietly paying up for balance-sheet durability and cash-flow visibility as rates stay uncertain. The second-order effect is that capital is likely to keep migrating from long-duration growth into dividend compounds, which compresses relative multiples for defensive megacaps while supporting funding conditions for high-payout sectors. In that setup, ABBV and PG are not just “safe” names—they become quasi-duration substitutes for investors who still need equity exposure but want lower drawdown risk.

The more interesting edge is in earnings resilience versus headline yield. PG’s setup is more about pricing power and volume stability than yield alone; if input costs stay benign, incremental margin upside can re-rate the stock faster than the market expects. ABBV has a cleaner earnings surprise path because the market is still anchored to legacy-product decay, so any evidence that the new immunology franchise offsets the cliff will extend multiple expansion over the next 2-3 quarters.

EPD is the contrarian income trade: the market often underestimates fee-based midstream cash flows because energy is mentally bucketed as cyclical, but the real driver is throughput and contract structure. The risk is not commodity price volatility; it is a regime shift in volumes or a sudden funding-cost shock if credit spreads widen materially. That makes EPD most attractive on weakness in rate-sensitive tape, but least attractive if investors rotate aggressively back into growth and higher beta.

Consensus is probably underestimating how sticky this “defensive dividend” bid can be if volatility stays elevated. The flip side is that these are crowded hiding places: if macro data stabilize and real yields back up, the relative-performance trade could reverse quickly over 1-2 months even if fundamentals remain intact. That argues for expressing the view tactically rather than as an all-weather substitute for tech exposure.

Key Decisions for Investors

• Long ABBV vs. XLV on a 3-6 month horizon: express the view that new-drug confidence and defensive rotation can outperform the broader healthcare basket by 5-8% if risk-off persists; cut if pharma leadership broadens and the single-name premium compresses.
• Buy PG on weakness for a 6-12 month hold: best risk/reward among the three if you want low-volatility compounding; use prior drawdown lows as entry and target modest multiple re-rating plus 3% yield carry.
• Initiate EPD as an income carry trade into any rates-backed pullback: 12-18 month hold for yield and slow distribution growth, but size smaller than ABBV/PG because financing spreads and energy sentiment can gap the unit price.
• Pair long PG / short an equal-dollar basket of high-multiple consumer discretionary names for 1-2 quarters: if consumer demand softens, staples should preserve margin while discretionary de-rates; good hedge for a slowdown scare.
• Avoid chasing all three after a sharp risk-off week; wait for a second-leg selloff or a rates-driven bounce to improve entry, since the trade is crowded and the near-term upside is more about relative defense than absolute fundamentals.